NCT02660281 - URMC Related Haplo-identical Donor BMT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 28, 2019

Study Completion Date

January 7, 2021

Conditions

Hematological DiseaseImmune DeficienciesSolid TumorsMyelofibrosisMultiple MyelomaLymphoma

Interventions

RADIATION

Total Body Irradiation 1200 cGy

1200 cGy TBI in 8 fractions

DRUG

Fludarabine

DRUG

Pre-Stem Cell Infusion Cyclophosphamide

Cyclophosphamide given prior to the stem cell infusion

DRUG

Pre-Stem Cell Infusion Mesna

Mesna given prior to the stem cell infusion

DRUG

Busulfan

DRUG

Melphalan

PROCEDURE

Stem Cell Infusion

Stem cell infusion

DRUG

Post-Stem Cell Infusion Cyclophosphamide

Cyclophosphamide given after the stem cell infusion

DRUG

Post-Stem Cell Infusion Mesna

Mesna given after the Stem Cell Infusion

DRUG

Thiotepa

Trial Locations (1)

Wilmot Cancer Institute, Rochester

All Listed Sponsors

lead

University of Rochester

OTHER